We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Viking Therapeutics VKTX is set to report fourth-quarter and full-year 2024 earnings on Feb. 5, after market close. Since the ...

With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

The Harrison County Community Foundation recently announced Samantha Carr as the recipient of the 2025 Lilly Endowment Community Scholarship for Harrison County. Carr is a senior at North Harrison Hig ...

Eli Lilly and Company (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. These products span ...

Visma’s acquisition signals a shared vision to simplify financial processes for businesses of all sizes. Known for its extensive portfolio of cutting-edge B2B cloud software, Visma is well-positioned ...

Dividend-screened portfolios of various kinds have failed to keep up with the broad US stock market over the past 10 years, ...

Eli Lilly And Co (LLY) stock saw a modest uptick, ending the day at $808.17 which represents a slight increase of $22.76 or 2.90% from the prior close of $785.41. The stock opened at $780.91 and ...

Ally Financial (NYSE:ALLY), formerly known as GMAC Inc., is a major player in the finance sector, offering a range of financial products and services. With a market capitalization of nearly $12 ...

Most analysts love Eli Lilly and, which has an average rating of buy. But there's reason to believe the stock may be overvalued at today's price of $785.41 per share. Let's look at the fundamentals ...

Viking Therapeutics struggles with FDA approval and scaling up. Find out why VKTX stock’s path remains uncertain, despite its ...